Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Income: 2015-2025

Historic Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$21.1 million.

  • Cartesian Therapeutics' Operating Income fell 19.86% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.5 million, marking a year-over-year decrease of 71.03%. This contributed to the annual value of -$43.9 million for FY2024, which is 49.20% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Operating Income is -$21.1 million, which was up 3.42% from -$21.8 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Operating Income ranged from a high of $13.9 million in Q2 2022 and a low of -$36.3 million during Q4 2023.
  • For the 3-year period, Cartesian Therapeutics' Operating Income averaged around -$17.7 million, with its median value being -$18.6 million (2023).
  • As far as peak fluctuations go, Cartesian Therapeutics' Operating Income surged by 2,966.37% in 2022, and later plummeted by 717.07% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Operating Income (Quarterly) stood at $4.1 million in 2021, then slumped by 308.34% to -$8.5 million in 2022, then slumped by 327.64% to -$36.3 million in 2023, then climbed by 26.43% to -$26.7 million in 2024, then dropped by 19.86% to -$21.1 million in 2025.
  • Its Operating Income was -$21.1 million in Q3 2025, compared to -$21.8 million in Q2 2025 and -$21.9 million in Q1 2025.